Add onc brain to your Home Screen: tap Share, then Add to Home Screen.
ENZARAD: 8yr MFS 74% vs 72%, HR 0.88 (p=0.34), enza added to RT+ADT misses overall; benefit isolated to cN1 / pelvic-RT pts.
Prostate carries the day's only signal. ENZARAD: enzalutamide layered on definitive RT + 2yr ADT does nothing for unselected high-risk localized disease (MFS HR 0.88, NS). Benefit confined to cN1 / pelvic-RT pts (MFS HR 0.43-0.47), but on prespecified, multiplicity-unadjusted subgroups, so hypothesis-generating.
read the full digest →Studies · 83
- ENZARAD (ANZUP 1303)8yr MFS 74% vs 72%, HR 0.88 (0.67-1.15) p=0.34: adding enza to RT+2yr ADT helps nobody overall; benefit isolated to cN1/pelvic-RT pts.
- ARS Appropriate Use Criteria: Locoregionally Recurrent Rectal CancerR0 (margin-negative) resection drives survival and local control; preop chemo/RT and reirradiation aid downsizing; consensus advises no major practice change.
- PRIMARY2PSMA-PET avoided biopsy in 49% while staying non-inferior for csPCa detection (12% vs 16%) vs systematic biopsy in high-risk equivocal-MRI men.
- INDIBLADE2-yr bladder-intact EFS 78% (0.67-0.9), OS 96% (0.91-1) after induction ipi+nivo then chemoRT in cT2-4aN0-2 MIBC.
- DOREMY5yr local recurrence-free survival 97.4% with reduced 36 Gy preop RT in myxoid liposarcoma; mature long-term dose de-escalation data.
- REVELUTIONAdjusted 12-mo total coronary plaque volume rose 68.9 mm³ more with leuprolide vs relugolix in men on pelvic RT + ADT.
- KEYNOTE-689 vs NIVOPOSTOPTwo positive phase III IO trials in resectable LA-HNSCC: perioperative pembro (EFS+) vs postoperative nivo (3yr DFS ~63 vs 53%), both layered on surgery+adjuvant CRT.
- GEC-ESTRO APBI Patient Selection Guidelines (2026 update)2026 update expands APBI eligibility to pTis/T1-2 ≤30mm, pN0/pN1mi, all histologies; contraindicated for BRCA, age <40, TNBC, EIC+, or extensive LVI.
- EAU 2026: MDT/SBRT Intensification in Oligometastatic Prostate Cancer (Fonteyne)review: MDT/SBRT delays progression and defers systemic Tx in oligomet HSPC; ARTO is the first RCT hinting at an OS benefit.
- NRG Oncology/RTOG 0848Adjuvant chemoRT did not improve OS overall (HR 0.96, p=0.38); node-negative subgroup gained OS (5yr 48.1% vs 28.6%).
- RAPCHEM (BOOG 2010-03)10-yr LRR 2.9% overall with response-adapted RT de-escalation post-NAC; low across all risk strata.
- NRG Oncology RTOG 053910-yr PFS 85.2%, 72.2%, 42.5% for low/intermediate/high-risk WHO grade 1-3 meningioma at median ~12yr f/u.